Ask AI
Search
Updates
Library
Diseases
Studies
Pathways
Calculators
Findings
Drugs
Preview
Specialties
Home
New Question
Answer
Pembrolizumab, a monoclonal antibody that targets the programmed death-1 (PD-1) receptor, plays a significant role in the treatment of colon cancer, particularly in cases of microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) metastatic colorectal cancer (CRC).
2.
Management of metastatic disease, systemic therapy, first-line
4.
5.
FDA approval summary: pembrolizumab for the first-line treatment of patients with MSI-H / dMMR advanced unresectable or metastatic colorectal carcinoma
3.
Treatment of cancer in adults (microsatellite Instability-High, mismatch Repair Deficient)
1.
Treatment of cancer in adults (high tumor mutational burden)
In conclusion, pembrolizumab plays a significant role in the treatment of MSI-H/dMMR metastatic CRC as a first-line therapy, offering a targeted approach for patients with these specific genetic markers.
References
1
Pembrolizumab
Dosages
2
Colon cancer
Medical management
Show all references